Exosome Characterization & Quality Analytics
OverviewServicesSamplesAdvantagesApplicationsCase StudyFAQs
Overview
Service Overview
At Creative BioMart Microbe, we provide comprehensive exosome characterization and quality analytics services tailored specifically for microbial extracellular vesicles (mEVs), including bacterial outer membrane vesicles (OMVs), probiotic-derived exosomes, and phage-derived vesicles. Our platform is built on MISEV2023 and ISEV best-practice guidelines, delivering critical quality attributes (CQAs) that support clients from early discovery through process development, CMC documentation, and regulatory filing. Unlike generic mammalian EV service providers, we have optimized every protocol for microbial membrane compositions—quantifying LPS, outer membrane proteins (OMP), and lipoteichoic acids (LTA) with validated assays that reflect the true biophysical and biochemical identity of microbial exosomes.
Figure 1. Schematic overview of the tiered exosome characterization and quality analytics workflow.
Creative BioMart Microbe offers end-to-end microbial exosome analytics, from sample receipt to validated data delivery. Explore the full Microbial Exosome Services ecosystem to see how characterization integrates with upstream production and downstream functional validation. Contact us for a custom quote and project consultation.
Services
Service Workflow
Service Details
Physical & Particle Profiling
This service establishes the physicochemical identity of microbial exosome preparations. NTA quantifies particle concentration and size distribution, while TEM and Cryo–EM resolve morphology and membrane integrity. DLS measures polydispersity index for homogeneity, and Zeta Potential analysis quantifies surface charge to predict colloidal stability.
Biochemical Marker & Composition Analysis
We validate universal and microbial-specific quality attributes. Standard markers (CD9, CD63, CD81) are detected by Western Blot or nanoflow cytometry, while microbial-specific OMP, LPS, and LTA are quantitated by validated assays. Purity is assessed by membrane-integrity quantification, nanoflow cytometry, and negative-marker screening. Protein and lipid content are measured.
Multi-Omics Cargo Profiling
This service uncovers the complete molecular payload. sRNA-seq and miRNA profiling (qPCR or NGS) identify regulatory RNAs. LC-MS/MS proteomics via MASCOT and Scaffold delivers protein identification and quantification. Lipidomics and metabolomics complete the fingerprint. All projects include bioinformatics analysis—differential expression, pathway enrichment, and visualization—delivered as a standalone report.
Functional Potency & Bioactivity Assessment
For therapeutic or functional applications, this service bridges characterization to biological relevance. We measure cellular uptake by fluorescence microscopy and flow cytometry. Immunomodulatory potency is quantified via T-cell proliferation inhibition, macrophage polarization, and cytokine profiling. Target-specific enzymatic, angiogenic, and cell-migration effects are assessed per mechanism of action.For mechanism-driven biological validation, our companion Functional Validation & Mechanism of Action Studies bridge analytical CQAs to therapeutic relevance.
Service Specifications & QC Standards
Analytical Capability
- Our platform covers physical profiling (NTA, TEM, Cryo-EM, DLS, Zeta Potential), biochemical validation (WB, capillary Western, nanoflow cytometry, OMP/LPS/LTA quantification), multi-omics (sRNA-seq, proteomics, lipidomics, metabolomics), and functional bioactivity assays. Each method is validated with positive and negative controls, and instrument calibration is performed per batch.
Typical Data Range
- Particle size: 30–200 nm (mode ~80–150 nm for bacterial OMVs)
- Particle concentration: 1×109 – 1×1012 particles/mL (sample dependent)
- Purity (protein/particle ratio): >2.0×109 particles/μg protein (benchmark)
- Zeta potential: –30 to –10 mV
- Membrane integrity: >70% lipid-bound particles (by fluorescent NTA)
Turnaround Time
| Project Type |
Timeline |
| Physical profiling package |
2–3 weeks |
| Biochemical analysis package |
2–4 weeks |
| Multi-omics package |
4–6 weeks |
| Full characterization bundle |
6–8 weeks |
| Expedited analysis |
Custom quote |
Timeline may vary based on sample complexity and assay customization.
Deliverables
- Raw data files (NTA video files, MS raw data, sequencing FASTQ)
- Processed analytical report with charts and statistical analysis
- Certificate of Analysis (CoA)
- Methodology summary and instrument calibration records
- Bioinformatics analysis report for multi-omics projects (pathway enrichment and visualization)
Quality Control
- Batch-level instrument calibration with positive and negative controls
- Inter-batch consistency assessment (NTA CV <20%)
- MISEV2023 compliance checklist
- Contaminant screening for cell debris, protein aggregates, and residual media
- Optional CQA documentation package for IND-enabling studies
All CQA data packages are designed to support release testing for Application-Grade Manufacturing and Formulation & Stability scale-up programs.
Sample Requirements
| Required Information |
Optional Information |
Not Accepted |
- Sample type (bacterial culture supernatant, OMV purified fraction, phage preparation, yeast EV)
- Estimated particle concentration or total protein yield
- Strain background and culture conditions
- Sample volume (≥500 μL recommended)
|
- Prior isolation and purification method (TFF, SEC, ultrafiltration, etc.)
- Target application (research, CMC, regulatory filing)
- Special assay requests (fluorescent NTA, functional potency)
- Control sample requirements
|
- Samples subjected to more than three freeze-thaw cycles
- Samples with unidentified strain origin or undocumented culture conditions
- Severely degraded, contaminated, or detergent-heavy preparations
- Samples preserved with fixatives or antimicrobial agents
|
Note: For projects requiring upstream strain construction and bioreactor optimization prior to analytical characterization, explore our Exosome-Producing Strain Engineering & Fermentation Optimization service for integrated handoff.
Our Advantages
- Microbial EV Specialization: Deep expertise in bacterial OMVs and phage-derived vesicles, with analytical protocols optimized for microbial membrane compositions rather than generic mammalian EV templates.
- Rapid Turnaround: Standard physicochemical packages are delivered in 2–3 weeks and multi-omics projects in 4–6 weeks, with milestone updates at every QC checkpoint.
- Flexible Service Packages: Tiered service options scale seamlessly from discovery screening to GMP-grade QC without vendor switching or method re-validation.
- Integrated Production-Analytics Loop: Seamless handoff from upstream strain engineering and fermentation optimization to downstream characterization ensures full traceability and consistent batch quality.
- Regulatory-Ready Documentation: Comprehensive CoA, method summaries, and optional CQA documentation packages suitable for IND-enabling studies, cosmetic raw material registration, and food-grade safety filings.
Applications
Biomarker Discovery & Liquid Biopsy Development
Multi-omics profiling of microbial exosomal cargo identifies disease-associated RNA and protein signatures for preclinical biomarker validation and companion diagnostic development.
Therapeutic EV Process Development & CMC Support
Batch-to-batch CQA monitoring and regulatory-ready data packages that accelerate therapeutic EV transition from preclinical development to clinical manufacturing.
Probiotic, Cosmetic & Food-Grade Raw Material QC
Functional potency validation for probiotics, safety profiling for cosmetics, and gastrointestinal stability assessment for food-grade mEV raw materials.
Vaccine Adjuvant & Drug Delivery Carrier Characterization
OMV-based vaccine adjuvant qualification and drug carrier assessment for loading efficiency, release kinetics, and target-cell uptake validation.
Case Study
Case Study 1: Paper-Based Vertical Flow Assay for Rapid Exosome Biomarker Profiling
A proof-of-concept study published in Biosensors (2025) demonstrated that a paper-based Vertical Flow Assay (VFA) can reliably detect and profile exosome surface biomarkers using an enzymatic colorimetric readout. The assay was configured in an ELISA-like format on a nitrocellulose membrane, capturing exosomes derived from metastatic breast cancer cell lines (SKBR3 and MDA-MB-231) via monoclonal antibodies against the tetraspanin receptors CD9, CD63, and CD81, as well as the epithelial marker EGFR1. An alkaline phosphatase (ALP)-conjugated secondary antibody catalyzed the conversion of NBT/BCIP substrate into an insoluble indigo precipitate, generating a visual signal that was quantified by smartphone imaging within 15 minutes. Comparative validation against bead-based flow cytometry confirmed consistent biomarker expression profiles across both cell lines, including the relative abundance patterns of CD63 and EGFR1. With a limit of detection of approximately 6 × 107 exosomes μL-1 and a total assay time under 20 minutes, this enzymatic VFA approach offers a simplified, cost-effective alternative to conventional flow cytometry for exosome characterization in research and clinical laboratory settings.
Figure 2. Characterization by NTA and Cryo-TEM micrographs of purified EV samples from SKBR3 (A) and MDA-MB-231 (B) breast cancer cell lines. (Pallarès-Rusiñol, et al. 2025)
Case Study 2: Multi-Modal Characterization of Human Breast Milk-Derived Exosomes for Anti-Inflammatory Efficacy
A study published in Journal of Neuroinflammation (2025) demonstrated that human breast milk-derived exosomes (HBME) attenuate lipopolysaccharide-induced microglial activation. Researchers isolated purified HBME and performed multi-modal characterization: NTA and TEM confirmed a 50–150 nm diameter range with canonical morphology; Western blot verified tetraspanin markers CD9, CD63, and CD81 in lysates; and FACS (ImageStream) confirmed surface expression of these markers on intact exosomes against isotype controls. Following rigorous quality verification, functional assays showed that these characterized HBME downregulated the TLR4/MyD88/NF-κB cascade in murine BV2 and human HMC3 microglia, reducing proinflammatory CD40, NLRP3, and IL-1β while restoring IL-10. This work highlights how comprehensive physicochemical and biochemical characterization establishes the essential foundation for interpreting exosomal functional potency and therapeutic mechanism.
Figure 3. Characterization of human breast milk-derived exosomes (HBME). (Akinduro, et al. 2025).
FAQs
Q: What types of microbial exosomes can be characterized?
A: We characterize bacterial outer membrane vesicles (OMVs), probiotic-derived exosomes, phage-derived vesicles, yeast extracellular vesicles, and other microbial EV preparations.
Q: How much sample volume is required for a full characterization package?
A: The physical and biochemical package requires a minimum of 500 μL. Multi-omics projects are best supported with at least 1 mL or 100 μg total protein. Low-input custom protocols are available upon consultation.
Q: What is the difference between standard NTA and fluorescent NTA?
A: Standard NTA detects all particles indiscriminately. Fluorescent NTA (fl-NTA) uses membrane-specific dyes to count only intact lipid-bilayer-enclosed vesicles, excluding protein aggregates and non-vesicular impurities for a truer purity assessment.
Q: Can you perform batch-to-batch consistency analysis for GMP-grade EV manufacturing?
A: Yes. We provide statistical comparison of particle size, concentration, marker expression, and purity across manufacturing batches, together with CQA trending analysis for release documentation.
Q: Do you provide bioinformatics support for multi-omics data?
A: Yes. Every multi-omics project includes differential expression analysis, pathway enrichment, biomarker prioritization, and interactive visualization delivered as a standalone interpretive report.
Q: What quality standards do you follow for microbial EV characterization?
A: All protocols are designed in alignment with MISEV2023 guidelines and ISEV best practices. We can adapt documentation to meet FDA, EMA, or regional cosmetic and food-safety regulatory requirements.
Q: How should samples be shipped to ensure stability?
A: Ship frozen at –80°C on dry ice. Avoid repeated freeze-thaw cycles. We provide a detailed shipping guideline and perform incoming quality inspection upon receipt.
Q: Can functional potency testing be added to a standard characterization package?
A: Yes. Cellular uptake, immunomodulation, enzymatic activity, and other functional modules can be integrated as upgrade options into any standard package.
References:
- Pallarès-Rusiñol, A., et al. (2025). Exosome Biomarker Profiling Using a Paper-Based Vertical Flow Assay. Biosensors, 15(10), 694.
- Akinduro, O., et al. (2025). Human breast milk-derived exosomes attenuate lipopolysaccharide-induced activation in microglia. Journal of Neuroinflammation, 22(1), 41.
